Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies
Covered in this story
Call it yourself
No calls on $KYTX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Kyverna Therapeutics →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.